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Chemical Induction of Oncogene Mutations
and Growth Factor Activity in Mouse Skin
Carcinogenesis
by B. BailIeul,*t K. Brown,* M. Ramsden,*t R. J. Akhurst,§
F. Fee,* and A. Balmain*II
The goal ofunderstanding the molecular basis ofhuman tumor development has been greatly facilitated
bythe use ofanimal model systems in which the etiology oftumordevelopment can becarefully controlled.
Environmental chemicals, eithernaturallyoccurring orartificially produced, are thought to make amajor
contribution to the human tumor burden. Many ofthe concepts ofmultistage carcinogenesis have been de-
veloped and refined usingthe mouse skin model system and the work described in this article has been car-
ried out in an attempt to analyzethe molecular changes that are associated with the initiation oftumorde-
velopment, the selection ofinitiatedcells to form papillomas, ortheprogression ofpremalignant tumors to
carcinoma. We have analyzed a number ofskin tumors induced in mice by a two-stage initiation and pro-
motion protocol and have detected a high frequency ofc-ras oncogene mutations in this system. The muta-
tion found in each case correlates well with the known reactivity ofthe carcinogens used. It has also been
shown that where ras activation occurs this represents an early event in the tumormodel system. Transform-
ing growth factor P is induced in mouse skin by tumor promoter treatment and may therefore play a role
in the selection ofinitiated cells to form papillomas. Additional events, some ofwhich involve the loss of
normal ias alleles andpossibly tumor suppressor genes, appear to takeplace at a later stage ofcarcinogenesis.
Introduction
A great deal of information has been accumulated on
the genetic toxicology ofchemical carcinogens present in
the environment. Some of these chemicals give rise to
specific DNA modifications and consequently induce mu-
tations in cellular DNA. However, the nature of such
events and the specific biological responset that are in-
duced in exposed cells are still unclear.
Animal model systems have been very useful for
studies ofthese questions. A wealth of information has
been obtained on the processes ofinitiation, promotion,
and progression using the mouse skin model system (1),
which we have employed in studies on the molecular
events associated with the different stages ofcarcinogen-
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esis. Most ofthe work to be described will be related to
mechanisms ofinitiation, butfurtherevents inpromotion
and progression will also be discussed.
Initiation Protooncogenes as
Targets for the Action of Chemical
Carcinogens
The critical biological targets for mutagenic action of
chemical carcinogens were unknown until the discovery
of cellular protooncogenes. These have been shown to
play an important role in the control ofcell growth and
differentiation(2)andmaybe capable ofactivation by en-
vironmental chemicals or radiation (3). Different genetic
changes have been shown to activate protooncogenes to
an oncogenic state, including single pointmutations, gene
amplification, translocations, or deletions (4).
ras Gene Activation
The individual members ofthe ras family ofprotoon-
cogene known as Harvey-(Ha), Kirsten-(Ki), and N-ras
are found to be activated in 10 to 40% ofhuman tumorsBAILLEUL ETAL.
(5). Ourprevious experiments on the role ofoncogenes in
mouse skin carcinogenesis showed that amember ofthis
family (Ha-ras) was reproducibly activated bypoint mu-
tations in both papillomas and carcinomas initiated with
dimethylbenz[a]anthracene (DMBA) (6-8).
The Has-ras was also foundto be mutatedin chemically
induced rat mammary gland (9), while either the N-ras
or K-ras gene was activated in rat thymic lymphomas
(10). Some tissue specificity ofras activation is alsofound
in human tumors. The Ha-ras gene has beenfound most
frequently activated in squamous carcinomas and mela-
nomas, whereas N-ras is foundpredominantly in tumors
ofhematopoietic cells. The Ki-ras is activated in a wide
spectrum ofmalignancies ofdifferent types but shows a
very high prevalence for activation in human colon
tumors (5). Almost all the activated forms observed were
by point mutation in the coding sequence of ras genes,
with hotspots located at codons 12, 13, and 61(11).
The reasons for specific activation of members of the
ras family in different tissues are unclear. One possibil-
ity is that specific mutagenesis takes place in one mem-
ber ofthe ras family in aparticular tissue. Alternatively,
each rasgene maybe equally susceptible tomutation, but
tissue-specific selection mechanisms may operate to en-
courage the outgrowth of a cell containing a particular
mutation. The activation pattern seen could also be due
to varyingtranscript levels in different tissues (12). This
seems unlikely to be the explanation, however, since
epidermnal cells express higherlevels ofKi-ras transcripts
than Ha-ras transcripts (unpublished results), but only
the latter is found to be mutated in tumors.
Transcriptional Control of the Mouse
Ha-ras Gene
The mouse Ha-ras gene hasbeen demonstrated to have
animportant role in skin carcinogenesis. However, some
tumors ofeither animal orhuman origin do nothavepoint
mutations in the structural gene but rather show in-
creased expression ofthe normal protooncogene product
(13). We therefore undertook a study of the transcrip-
tional control elements of this gene, as these elements
could be important alternative targets for chemical muta-
genesis.
A genomic clone of the normal Ha-ras gene (AN1-ras)
was obtained and restriction mapped. Full details ofthis
sequence willbepublished elsewhere (14). Figure 1 shows
the sequenced region of Al-ras and indicates that the
clone contains the first two coding exons of the Ha-ras
gene, butlacks exons 3 and4. The sequenced data ofthe
clone has been compared to that ofboth rat (15) and hu-
man (16).
The presence in AN1-ras of the first exons together
with 20 the kb upstream sequence enabled us to inves-
tigate the transcriptional control ofthisgene in some de-
tail. A combination ofnucleotide sequencing, primer ex-
tension analysis and Si mapping was used to show that
initiation oftranscription starts at the three sites shown
in Figure 1. The upstream region containing the tran-
scription start sites (exon-1) is highly conserved between
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FIGURE 1. The structure and promoter activity of the mouse Ha-ras
gene 5'flankingsequence, Primerextension analysis and Si mapping
show three transcription start sites (arrows) in exon-1. The shaded
box represents a sequence within the first intron that is highly con-
served between mouse and human DNA. The openlioxes represent
either coding(1 and 2) ornoncoding(-1) exons. The CAT enzyme ac-
tivities obtained with three constructs have been compared. The first
one showed significant enzyme activity compared to the promotor-
less gene. The inclusion ofthe first intron increased promoter activ-
ity by 5- to 10-fold.
mouse and human and contains several potential SP1
(promoter-specific factor) binding sites, similarto the pro-
moterregions ofanumberofcellularhousekeepinggenes
(17).
The promoter activity of this sequence was directly
tested by fusion to a promoterless chloramphenicol-
acetyl-transferase gene (CAT) followed by transfection
into 208F fibroblast cells and an assay for CAT enzyme
activity. The results are in agreement with the promoter
activity found in the exon-1 region of the human gene
(18,19). Interestingly, the inclusion ofthe first intron in
the fusion construct increased substantially the promoter
activity of the exon-1 region (Fig. 1), suggesting that a
previously undetected enhancer element may be present
within this intron (14). A possible candidate for this en-
hancer element could be ahighly conserved sequence of
about 300 bp found in the first intron (14).
To date, single point mutations within the coding exon
seem to be the only differences detectable that confer
dominanttransforming activity. It remainspossible that
additional mutation maybe found within theputative en-
hancer region or within the housekeeping promoter re-
gion, which could lead to elevated expression in some
tumors.
Carcinogen-Specific Mutations in the
Ha-ras Gene
A single treatment with a variety of carcinogens (Ta-
ble 1) can accomplish the initiation ofmouse skin carcino-
genesis. The list ofinitiators includes both direct-acting
alkylating agents and derivatives requiringmetabolic ac-
tivation such as polycyclic aromatic hydrocarbons and
heterocyclic aromatic amines. Chemicals of these two
classes are known to induce different types ofpoint mu-
tationsbyformingspecificpromutageniclesionswith the
DNA. N-methyl-N-nitro-nitrosoguanine (MNNG) causes
GC to ATtransitions by miscoding during DNAreplica-
tion (19). Bulky adducts formed by polycyclic hydrocar-
bons (20) and heterocyclic aromatic amines such as
4-nitroquinoline-1-oxide (4-NQO) (21,22) cause predom-
inantly transversion and transition mutations. respec-
tively. We have therefore investigated the types of on-
-
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Table 1. Initiators and promoters of mouse skin carcinogenesis.
Initiators
Benzo[a]pyrene
Dimethylbenzanthracene
Methylcholanthrene
N,N'-Dimethylnitrosourea
N-Methyl-N-nitro-nitrosoguanidine
4-Nitroquinoline-1-oxide
P-Propiolactone
bis(Chloromethyl) ether
cogene mutations that can be found in tumors initiated
with these different mutagens. Ifthe oncogene mutations
detected have the correct carcinogen specificity, this
would provide strong evidence that the mutation takes
place duringinitiation by direct interaction between thie
carcinogen and the oncogenic DNA.
The main conclusion obtained from the results (Table
2) is that the type ofHa-ras mutation seen is dependent
upon the initiating agent used. An AT--TAtransversion
mutation is seen in a very high proportion ofthe tumors
initiated with DMBA. A substantial proportion of the
MNNG-induced tumors exhibited the GC to AT transi-
tion predicted on the basis ofthe known mechanisms of
action ofthis carcinogen (19). This mutation had not been
seen in any tumors initiated with the polycyclic hydrocar-
bons, but has been found with 4-NQO (B. Bailleul and
A. Buchman, unpublished data).
In contrast, no effect on the mutations has been ob-
served by using different promoting agents. These
results therefore supportthe conclusionthatthe ras mu-
tations are induced at an early stage or carcinogenesis (7)
and probably at the time of initiation (8,9).
Promotion: Molecular Events in
Skin Tumor Promotion
Tumorpromotions elicit awide range ofmorphological
andbiochemical changes when applied to cells in culture
or to mouse skin in vivo (1). These include the induction
ofthe synthesis ofRNA, DNA, and protein that accom-
Promoters
Those that bind, protein kinase C
12-0-Tetradecanoylphorbol-13-acetate
Dihydroteleocidin
Others
Phenol
Anthralin
Chrysarobin
Skin wounding
panies the phases ofcellularproliferation and differenti-
ation. An important advance in our understanding oftu-
morpromotion was the recognition of a cellular receptor
'for 12-0-tetradecanoylphorbol 13-acetate (TPA) which
copurified with protein kinase C (23). Activation of this
kinase by TPA is responsible for initiation of a complex
chain of events, which in mouse skin culminates in the
selection ofinitiated cells from the background ofnormal
cells. Yuspa and co-workers have postulated that resis-
tance to terminal differentiation induced by the tumor
promoter TPA is an important factor in initiated cell
selection (24).
The endogenous inducers ofepidermal differentiation
are unknown. We have investigated the early effects of
TPA on the temporal and spatial expression patterns of
the gene encoding TGF-P-1 (TGF-P), a negative growth
regulator that has been shown to affect the growth and
differentiation properties of epithelial cells in vitro
(25,26). It haspreviously beenpostulated thatTGF-P may
play a role in tumorpromotion (27), but the main source
of TGF-f was thought to be platelets or macrophages
released duringthe process ofinflammation orwounding
(28). Northern blot analysis using a cloned TGF-P probe
(29) has now shown that this growth factor is highly in-
duced in mouse epidermis by treatment with the tumor
promoter TPA (31). Furthermore, in situ hybridization
to tissue sections shows that the TGF-P expression takes
place predominantly in the differentiating epidermal cells
(30). TGF-f mRNAis also induced in the hairfolliclesby
TPA treatment, again in cells that are undergoingtermi-
nal differentiation.
Table 2. Ha-ras gene activation in mouse skin tumors.
Tumor Carcinogena Promoter No. analyzed Ha-ras activation Mutation
Papilloma DMBA TPA 42 39 A182- T
1 Codon 61
Papilloma DMBA Chrysarobin 5 5 A182- T
Carcinoma DMBA TPA 13 FlO A182- T
L1 G35- T
Carcinoma DMBA DMBA 8 4 A182- T
Papilloma MCA TPA 5 2 A182- T
Carcinoma MCA TPA 7 1 Codon 12/13
Papilloma BaP TPA 2 1 G35- T
Carcinoma BaP TPA 3 1 G35- T
Papilloma MNNG TPA 14 11 G35- A
Carcinoma MNNG TPA 9 1 G35- A
Papilloma 4-NQO TPA 4 2 G35- A
aAbbreviations: DMBA, dimethylbenzanthracene; MCA, methylcholanthrene; BaP, benzo[a]pyrene; MNNG, N-methyl-N-nitro-N-nitrosoguanidine;
4-NQO, 4-nitroquinoline-1-oxide.
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These results provide a possible explanation for the
selection ofinitiated cells by TPA treatment. Ifinitiated
cells have a block in the growth inhibitory or differenti-
ation responses to TGF-f3, this could provide a selective
advantage each time the TPA treatment is carried out.
However, the process ofpromotion is undoubtedly com-
plex and probably involves the action ofboth positive and
negative growth regulators. A series of experiments is
in progress to test these hypotheses and consequently
elucidate the role playedbygrowthfactors intumorpro-
motion.
Chemicals in Tumor Progression
There isevidenceforoncogene involvementinprogres-
sion ofthe tumorigenicphenotype from studies on human
tumors. In the late stages ofdevelopment ofhuman neu-
roblastomas, one ofthe mycgenefamily members is am-
plified, and the degree ofamplification can be correlated
with prognosis (31). In the mouse skin model system,
changes in addition to single point mutation inras genes
seem necessaryfor tumorprogression, since manypapil-
lomas with such mutations regress spontaneously.
Malignant conversion ofmouse skintumors is increased
by treatment of the papillomas with chemicals such as
MNNG or4-NQO (32), butnotby treatment with the tu-
mor promoter TPA. These two compounds have been
used to induce tumorigenic progression ofhuman epider-
mal keratinocytes previously immortalized by adenovirus
12 and simian virus 40 (33).
Amplification ofthe Ha-ras gene locus mayplay arole
in progression by increasing the expression level ofthe
mutated ras allele (8). Other results have recently been
obtained showingthatthe normal allele was absentfrom
carcinomas that had amplified a mutated Ha-ras allele
(unpublished results from thislaboratory). Abiastoward
transcription ofthe mutant ras allele has been observed
previously in human carcinoma cell lines (16,34).
Loss ofanti-oncogenes or tumor suppressorgenes may
constitute a very important step in tumor progression,
and it ispossible thatthe karyotypic changes very often
found in the late stage ofcarcinogenesis involve loss or
inactivation ofsuch sequences. Since the chemical agents
that induceprogression mostefficiently are not the best
initiators, itistemptingto speculate thatqualitatively dif-
ferent events areinvolved. Forexample, DMBAis avery
strong initiating agent, presumably since it efficiently in-
duces point mutation in the coding sequence of Ha-ras,
but is arelatively poorprogressing agent. Otherpolycy-
clic aromatic compounds and4-NQO are weak initiators
but relatively good progressors, because they induce a
higher conversion rate of papilloma to carcinomas (35;
T. J. Slaga, personal communication).
One ofthe most effective progressing agents in mouse
skin is4-NQO, whichhasbeen studiedin aforwardmuta-
genesis in E. coli as previously used with aminoacetoxy
fluorene (AAF)(36). This study showed thatthe main ad-
duct formed by4-NQO on the N-2 oftheguanine (22) in-
ducedframeshift mutations in ahotspot sequence which
is GC rich (M. H. Loucheux-lefebvre, personal communi-
cation). Ifsimilar frameshift mutations are seen in mam-
malian cells, these might be expected to lead to inactiva-
tion of genes rather than to activation of transforming
genes by single point mutations.
In conclusion, the quantitative differences in the abili-
ties ofchemical mutagens to induce progression may re-
flect qualitative differences in theirmechanisms ofaction.
Certain agents may be more efficient progressors be-
cause the mutations theyinduce are more likely to delete
or inactivate genes rather than cause point mutations
that are normally associated withinitiating capacity. The
identification and cloning ofgenes involved in late stages
ofcarcinogenesis will provide new approaches to analy-
sis of the diverse mechanisms by which environmental
carcinogens induce neoplastic changes.
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